Prevnar 13
As of the edition of 20 October 2026, Prevnar 13 is a drug known only by a code name: marketed, first approved in 2010 (US); US protection ended in 2022.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Code name only
- Brand name
- Prevnar 13
- First approved
- 24 February 2010 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Registered trials
- 21, 3 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer; Immune system; Heart and blood vessels; Mouth and teeth
US protection
US protection ended in 2022.
US protection ended in 2022, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Pfizer. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 7 | 4 | 0 | 2 |
| Phase 3 | 7 | 7 | 0 | 0 |
| Phase 4 | 4 | 3 | 1 | 0 |
| All trials | 21 |